Cue Biopharma Q2 net loss $8.5M; BI deal with $12M upfront, $345M milestones

Cue Biopharma, Inc.

2025-Q2 EPS reported -$0.24 revenue$3,374,000

Net loss $8.5M ($0.09/share) vs $10.2M in Q2 2024; collaboration revenue $3.0M.
Announced collaboration with Boehringer Ingelheim for CUE-501: $12M upfront, up to $345M milestones.
Received FDA Pre-IND feedback supporting CUE-401 IND for autoimmune disease.
CUE-101 Phase 1 data: 50% ORR, 88% 12-mo OS, median OS 32 months in HPV+ HNSCC.
Raised ~$20M via public offering; cash position $27.5M at June 30.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.